The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes—A Scientometric Investigation and Visualization Study

Nov 27, 2024Medicina (Kaunas, Lithuania)

GLP1's role in body weight and blood sugar control in people with diabetes

AI simplified

Abstract

Semaglutide may lead to superior outcomes in weight management and cardiovascular health compared to other diabetes medications.

  • GLP-1 receptor agonists (GLP-1 RAs) can influence weight management and cardiovascular health in diabetic patients.
  • Dulaglutide and semaglutide are highlighted for their effects on body weight and cardiovascular disease management.
  • Semaglutide is associated with improved blood sugar control, reduced body weight, and lower cardio-metabolic risk factors in individuals with type 2 diabetes.
  • GLP-1 RAs may provide cardiovascular protection by affecting factors such as blood pressure and glycated hemoglobin (HbA1c) levels.
  • The 4GI model offers a new approach to evaluate the interactions of various medications in diabetes treatment.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free